Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients.

Autor: Malard F; Service d'hématologie clinique et de thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France. florent.malard@inserm.fr., Vekhoff A; Service d'hématologie clinique et de thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France., Lapusan S; Service d'hématologie clinique et de thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France., Isnard F; Service d'hématologie clinique et de thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France., D'incan-Corda E; Service d'hématologie, Institut Paoli Calmettes, Marseille, France., Rey J; Service d'hématologie, Institut Paoli Calmettes, Marseille, France., Saillard C; Service d'hématologie, Institut Paoli Calmettes, Marseille, France., Thomas X; Service d'hématologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France., Ducastelle-Lepretre S; Service d'hématologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France., Paubelle E; Service d'hématologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France., Larcher MV; Service d'hématologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France., Rocher C; Service d'hématologie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France., Recher C; CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III Paul Sabatier, Service d'hématologie, Toulouse, France., Tavitian S; CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III Paul Sabatier, Service d'hématologie, Toulouse, France., Bertoli S; CHU de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III Paul Sabatier, Service d'hématologie, Toulouse, France., Michallet AS; Service d'hématologie, Centre Léon Bérard, Lyon, France., Gilis L; Service d'hématologie, Centre Léon Bérard, Lyon, France., Peterlin P; Service d'hématologie, CHU Nantes, Nantes, France., Chevallier P; Service d'hématologie, CHU Nantes, Nantes, France., Nguyen S; Service d'hématologie clinique, Hôpital de la Pitié Salpétrière, APHP, Sorbonne Université, Paris, France., Plantamura E; MaaT Pharma, Lyon, France., Boucinha L; MaaT Pharma, Lyon, France., Gasc C; MaaT Pharma, Lyon, France., Michallet M; Service d'hématologie, Centre Léon Bérard, Lyon, France., Dore J; Université Paris-Saclay, INRAE, MetaGenoPolis, AgroParisTech, MICALIS, Jouy-en-Josas, France., Legrand O; Service d'hématologie clinique et de thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France., Mohty M; Service d'hématologie clinique et de thérapie cellulaire, Hôpital Saint Antoine, APHP, Sorbonne Université, INSERM UMRs 938, Paris, France.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2021 May 25; Vol. 12 (1), pp. 3084. Date of Electronic Publication: 2021 May 25.
DOI: 10.1038/s41467-021-23376-6
Abstrakt: Acute myeloid leukemia (AML) intensive chemotherapy combined with broad-spectrum antibiotics, leads to gut microbiota dysbiosis promoting pathological conditions and an increased incidence of complications. Here we report findings from a phase II single-arm, multicenter study evaluating autologous fecal microbiota transfer (AFMT) in 25 AML patients treated with intensive chemotherapy and antibiotics (ClinicalTrials.gov number: NCT02928523). The co-primary outcomes of the study are to evaluate the efficacy of AFMT in dysbiosis correction and multidrug-resistant bacteria eradication. The main secondary outcomes are to define a dysbiosis biosignature, to evaluate the effect of dysbiosis correction on patient clinical status, to assess the short and mid-term safety of AFMT in this immunocompromised population, and to evaluate the feasibility of the AFMT procedure and acceptability by the patient. Intensive induction chemotherapy induces a dramatic decrease of α-diversity indices, and a microbial dysbiosis with a significant shift of the microbial communities and domination of pro-inflammatory families. After AFMT treatment, α-diversity indices return to their initial mean levels and the similarity index shows the restoration of microbial communities. The trial meets pre-specified endpoints. AFMT appears to be safe and may be effective for gut microbiota restoration in AML patients receiving intensive chemotherapy and antibiotics, with an excellent gut microbiota reconstruction based on both richness and diversity indices at the species level.
Databáze: MEDLINE
Externí odkaz: